Dr. Reddy's Laboratories Limited (DRREDDY) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Total Assets Chart for Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited (DRREDDY) total assets for FY2026 were INR 579.3B, a 17.5% change from FY2025. Dr. Reddy's Laboratories Limited's total assets grew from INR 11.8B in 2001 to INR 579.3B in 2026 (4793.2% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 16.9%, 10-year CAGR of 10.8%, 20-year CAGR of 11.2%.
Total Assets (Indian Rupees)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ₹980.44B
- Implied Share Price
- ₹1177.00
- Enterprise Value
- ₹978.80B
- Revenue (TTM)
- ₹331.19B
- EBITDA
- ₹54.67B
- Profit Margin
- 10.00%
- Trailing P/E
- 29.76
- Forward P/E
- 26.95
- Price/Book (MRQ)
- 2.57
- Price/Sales (TTM)
- 2.96
- EV/EBITDA
- 14.68
- EV/Revenue
- 2.96
- Dividend Yield
- 0.68%
- Book Value
- ₹460.31
- Free Cash Flow (FY2026)
- ₹30.51B
- Free Cash Flow Yield
- 3.11%
Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.